Consensus Forward P/E: 14
Dividend Yield 2.46%
Average target price 118 € (28 analysts)
The company's pending acquisition presents unique risks to investors. Hence, share price was plummeting over months. Price bottom was reached after positive news about the Monsanto deal was going to be spread, market strong sentiment (e.g trade war fears) waned and smart money started to transfer money from tech stocks to big solid growth companies like Bayer.
For investors in Big Pharma this might be an interesting company (conglomerate) with several major segments that are a medical device business, a seed business and animal health.
I have my problems with the company's future and diversity, but investors might think differently on it.